

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

  
**Rainmed Medical Limited**  
**潤邁德醫療有限公司**  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 2297)

**POLL RESULTS OF ANNUAL GENERAL MEETING  
HELD ON JUNE 29, 2026**

Reference is made to the circular (the “**Circular**”) of Rainmed Medical Limited (the “**Company**”) and notice of the Annual General Meeting (the “**Notice**”) both dated April 29, 2026, and the announcement of the Company dated June 1, 2026 in relation to, among others, the withdrawal of the resolution of the Annual General Meeting (the “**Announcement**”). Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board is pleased to announce the Annual General Meeting was held on Monday, June 29, 2026 and all the proposed resolutions set out in the Notice were duly passed by the Shareholders by way of poll.

The poll results in respect of the resolutions passed at the Annual General Meeting are as follows:

| ORDINARY RESOLUTIONS |                                                                                                                                                                                                                         | Number of Votes<br>(approximate percentage (%)) |           |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|-----------|
|                      |                                                                                                                                                                                                                         | For                                             | Against   |
| 1.                   | To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries, and the reports of the Directors and the auditor of the Company for the year ended December 31, 2025. | 374,683,000<br>(100%)                           | 0<br>(0%) |

| ORDINARY RESOLUTIONS |     |                                                                                                                                                                                                                                                        | Number of Votes<br>(approximate percentage (%)) |               |
|----------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|---------------|
|                      |     |                                                                                                                                                                                                                                                        | For                                             | Against       |
| 2.                   | (a) | To re-elect the following retiring Directors:                                                                                                                                                                                                          |                                                 |               |
|                      |     | (i) Mr. Huo Yunfei as an executive Director;                                                                                                                                                                                                           | 374,683,000<br>(100%)                           | 0<br>(0%)     |
|                      |     | (ii) Mr. Zhu Zeke as an executive Director;                                                                                                                                                                                                            | N/A<br>(Note)                                   | N/A<br>(Note) |
|                      |     | (iii) Ms. Duan Jing as an executive Director;                                                                                                                                                                                                          | 374,683,000<br>(100%)                           | 0<br>(0%)     |
|                      |     | (iv) Mr. Chen Xuefeng as an independent non-executive Director;                                                                                                                                                                                        | 374,683,000<br>(100%)                           | 0<br>(0%)     |
|                      |     | (v) Mr. Zhao Hui as an independent non-executive Director; and                                                                                                                                                                                         | 374,683,000<br>(100%)                           | 0<br>(0%)     |
|                      | (b) | To authorize the Board to fix the remuneration of the Directors.                                                                                                                                                                                       | 374,683,000<br>(100%)                           | 0<br>(0%)     |
| 3.                   |     | To re-appoint SHINEWING (HK) CPA Limited as the auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix its remuneration for the year ending December 31, 2026. | 374,683,000<br>(100%)                           | 0<br>(0%)     |
| 4.                   | (A) | To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company as set out in the resolution numbered 4(A) of the Notice <sup>#</sup> .                                                                     | 374,683,000<br>(100%)                           | 0<br>(0%)     |
|                      | (B) | To grant a general mandate to the Directors to repurchase shares of the Company as set out in the resolution numbered 4(B) of the Notice <sup>#</sup> .                                                                                                | 374,683,000<br>(100%)                           | 0<br>(0%)     |
|                      | (C) | To extend the general mandate granted to the Directors to allot, issue and deal with shares of the Company by the number of shares repurchased by the Company as set out in the resolution numbered 4(C) of the Notice <sup>#</sup> .                  | 374,683,000<br>(100%)                           | 0<br>(0%)     |

<sup>#</sup> The full text of above resolutions are set out in the Notice.

*Note: As mentioned in the Announcement, resolution numbered 2(a)(ii) above is no longer applicable and has not been put forward for consideration and approval by the Shareholders at the Annual General Meeting.*

As more than 50% of votes were cast in favour of each of the resolutions numbered 1 to 4 above, all of the above ordinary resolutions were duly passed at the Annual General Meeting.

As at the date of the Annual General Meeting, the total number of issued Shares were 1,401,358,800 Shares, which was the total number of Shares entitling the Shareholders to attend and vote on the resolutions proposed at the Annual General Meeting. There were no treasury shares (as defined in the Listing Rules) held by the Company (including any treasury shares held or deposited with the Central Clearing and Settlement System) as at the date of the Annual General Meeting. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of any of the resolutions at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on any of the resolutions at the Annual General Meeting. None of the Shareholders has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Annual General Meeting.

All Directors have attended the Annual General Meeting in person or via electronic means.

Tricor Investor Services Limited, the Company's Hong Kong branch share registrar, acted as the scrutineer for the vote-taking at the Annual General Meeting.

By order of the Board  
**Rainmed Medical Limited**  
**Huo Yunfei**  
*Chairman of the Board and Executive Director*

Hong Kong, June 29, 2026

*As at the date of this announcement, the Board comprises Mr. Huo Yunfei and Ms. Duan Jing as executive Directors, Dr. Huo Yunlong, Mr. Wang Lin and Mr. Heng Lei as non-executive Directors, and Mr. Liu Shuen Kong, Mr. Chen Xuefeng and Mr. Zhao Hui as independent non-executive Directors.*